Publication
Article
Author(s):
Analysis of 2012-2021 commercial claims demonstrates that spending growth was concentrated among the highest spenders and there was increasing subsidy across enrollees through cost-sharing design.
ABSTRACT
Objectives: The annual mean spending measures typically used to study longitudinal trends mask distributional and seasonal variation that is relevant to patients’ perceptions of health care affordability and, in turn, provider collections. This study describes shifts in the distribution and seasonality of plan and patient out-of-pocket spending from 2012 through 2021.
Study Design: Analysis of multipayer commercial claims data.
Methods: Medical spending per enrollee was calculated by summing inpatient, outpatient, and professional services, which comprised plan payments and out-of-pocket payments (deductible, coinsurance, co-payment). To account for the long right tail of the spending distribution, enrollees were stratified by their decile of annual medical spending, and annual mean spending estimates were calculated overall and by decile. Mean spending estimates were also calculated by quarter-year.
Results: Inflation-adjusted medical spending grew most quickly among the highest decile of spenders, without proportional growth in their out-of-pocket expenses. Out-of-pocket spending increased for the majority of enrollees in our sample prior to the COVID-19 pandemic, in real dollars and as a share of total medical spending. Out-of-pocket spending was increasingly concentrated in the early months of the calendar year, driven by deductible spending, and was lower in 2020 and 2021, plausibly due to policies limiting cost sharing for COVID-19–related services.
Conclusions: Insurance is working well to protect the highest spenders at the cost of reduced insurance generosity among spenders elsewhere in the distribution. The increasing cross-subsidization among enrollees through cost-sharing design—vs premiums—is a trend to watch among rising public concerns about underinsurance and medical debt.
Am J Manag Care. 2024;30(9):415-420. https://doi.org/10.37765/ajmc.2024.89600
Takeaway Points
This study of 2012-2021 commercial claims describes distributional and seasonal spending variation relevant to patients’ perceptions of health care affordability.
Americans place health care affordability among the top problems facing the country.1 As election season approaches, the issue is likely to get increasing policy attention, particularly as estimates suggest roughly 1 in 4 middle-class Americans have medical debt.2 In the decade since the Affordable Care Act was implemented, the cost-sharing structure of health plans has evolved. Enrollment in high-deductible health plans has grown steadily, from 20% of workers in 2013 to 29% of workers in 2023.3 In the same time frame, mean deductibles have grown substantially, from $1135 in 2013 to $1735 in 2023 for an employee with single coverage.3
Although trends in employer-sponsored health insurance premiums are widely reported,4 understanding trends in health care spending among commercially insured enrollees—and member out-of-pocket (OOP) spending, in particular—is critical to this issue. However, reporting on spending trends has generally focused on annual patient-level total spending averages, which, although relevant for premiums, obscure underlying distributional OOP trends with important implications, particularly for patients’ perceptions of affordability and the feasibility of bill collection by providers.5,6
Prior studies have focused on the disproportionate OOP costs and financial burden for patients with certain conditions or plan characteristics,7,8 as well as the increasing burden on the highest-paying individuals,9,10 but not an overall population of commercial insurance enrollees. This study of multipayer commercial claims data from 2012 through 2021 presents a novel approach to spending measurement by describing longitudinal, distributional, and seasonal trends in both plan and OOP spending. Additionally, we report spending trends before and during the COVID-19 pandemic, providing insights on how the pandemic altered the spending trajectory across the distribution.
METHODS
We examined the Health Care Cost Institute’s 2012-2021 commercial insurance claims from Blue Health Intelligence, Aetna, and Humana. Enrollees younger than 65 years in commercial preferred provider organization (PPO), point-of-service (POS), health maintenance organization, and exclusive provider organization plans as their primary coverage for a full calendar year were included, regardless of whether they utilized services (see the eAppendix [available at ajmc.com] for sample attrition).
We measured medical spending (allowed amounts) per enrollee by summing across all inpatient, outpatient, and professional services. Total spending comprises plan payments and OOP payments, which include cost-sharing spending through deductibles, co-payments, and coinsurance. We focused on medical spending and excluded prescription drug spending covered under the pharmacy benefit because the Health Care Cost Institute data set does not include pharmacy claims for roughly half of enrollees in the analytic sample (likely because the included plans do not administer the pharmacy benefit for those enrollees). We replicated our analyses for the subset of enrollees with prescription drug coverage, including both medical and pharmaceutical spending, as a sensitivity analysis. All monetary values were adjusted to 2021 US$ using the Consumer Price Index for All Urban Consumers.
To illustrate longitudinal spending trends while accounting for the long right tail of the medical spending distribution, enrollees were stratified by their decile of total annual medical spending in each year (see the eAppendix for decile stratification details). Annual mean spending estimates were then calculated overall and for each decile. We also calculated mean spending measures by quarter-year to evaluate seasonal trends in spending over the decade.
We conducted a sensitivity analysis to assess whether longitudinal trends were biased by compositional changes in our sample over time. We used regression analysis to estimate mean annual total medical spending, plan spending, and member cost sharing, adjusting for enrollee age, sex, plan funding type, and plan product type (see the eAppendix for sensitivity analysis details).
RESULTS
Our sample included 329,446,097 enrollee-years spread across the 10-year study period. Most enrollees were in self-funded plans (70%) and had PPO (64%) or POS (26%) product types. The sample was half (50%) female, with a mean of 7 clinician visits or ancillary services (such as laboratory tests) and 1 outpatient visit per enrollee-year as well as a mean of 5 inpatient stays per 100 enrollee-years. Across all years, the mean total medical spending was $4315, including mean OOP spending of $632.
We found that inflation-adjusted mean total annual OOP medical spending per person increased from $578 in 2012 to a high of $683 in 2019 before declining to $587 in 2020 and somewhat rebounding to $647 in 2021 (Figure 1). However, there was considerable variation, with these increases primarily driven by patients in the upper half of the total medical spending distribution. Overall, mean annual total medical spending increased from $4034 in 2012 to $4774 in 2021 (18%), whereas among the top decile of spenders it increased from $28,328 to $34,506 (22%) over that time period (Figure 2). As a result, OOP spending as a percentage of total medical spending was lower (and relatively stable) for enrollees in the top decile of spending (14%-15% in all years in the study period) but increased for many enrollees across the distribution prior to the COVID-19 pandemic (Figure 3). Overall, OOP spending increased from 28% of total spending in 2012 to 31% of total spending in 2019 before falling to 27% and 25% in 2020 and 2021, respectively.
There were smaller reductions in total annual medical spending in 2020 and a faster rebound in 2021 compared with OOP spending. Overall, mean total spending declined from $4603 in 2019 to $4312 in 2020, increasing to $4774 in 2021 (Figure 4). In contrast, overall mean OOP spending declined from $683 in 2019 to $587 in 2020 and increased to $647 in 2021. As a result, the percentage of total spending paid OOP fell in 2020 and 2021, both overall and across all but the very lowest and highest ends of the distribution (Figure 3). These results were consistent with findings of adjusted analyses, as described in the eAppendix. These results were also similar for the subset of enrollees with pharmaceutical coverage, and seasonal and distributional trends were consistent when pharmaceutical and medical spending were combined.
We also observed seasonal fluctuations underlying total and OOP spending consistent with a typical health plan’s calendar year reset on deductibles and OOP limits (Figure 5). OOP spending is highest in the first quarter and lowest in the fourth quarter across all study years. The first to fourth quarter OOP gap increased from $56 in 2012 to a peak of $83 in 2019 prior to the pandemic onset. Total spending and plan spending were greatest in the last quarter of each year.
DISCUSSION
Our analysis of commercial claims offers several key insights related to trends in OOP spending. First, we found that OOP spending increased among enrollees across the upper half of the medical spending distribution. However, total medical spending increases were particularly concentrated among the top decile of spenders. As a result, prior to the COVID-19 pandemic, OOP spending as a share of total medical spending was increasing at all but the very highest and lowest ends of the spending distribution.
Our observation of lower spending during the pandemic is consistent with the results of a prior study on the medical spending of commercially insured individuals between 2018 and 2021, which found that spending decreased during the beginning of the COVID-19 pandemic in the US and recovered to prepandemic levels in 2021.11 Our finding of lower OOP spending in 2020 may be partially explained by this overall reduction. However, we also found meaningful changes in the percentage paid OOP starting in 2020, when both total and OOP spending dropped considerably. Although medical spending bounced back to pre–COVID-19 levels in 2021, OOP spending did not. This may have been due to prohibitions on OOP spending for COVID-19–related testing and care during this time. Further research could explore the types of services that drove these OOP spending reductions, and additional years of data could shed light on the extent to which we should expect these trends to continue over time.
Our findings suggest that insurance is working well to protect enrollees at the highest end of the spending distribution from exorbitant OOP spending growth as their medical spending rises notably. Although we did not observe proportional levels of growth in their OOP obligations (relative to medical spending growth), we nonetheless observed increases in the magnitude of inflation-adjusted OOP spending among these enrollees over time, in addition to high levels of OOP spending relative to other enrollees.
In some sense, this insurance protection at the high end of the spending distribution has come at the cost of reduced insurance generosity among spenders elsewhere in the distribution, who paid an increasing share OOP prior to the COVID-19 pandemic. These measurements demonstrate that the shift toward high-deductible insurance design has increased cross-subsidy within pools of commercial insurance enrollees through OOP spending. This has enabled premiums to remain lower than they otherwise would without shifts in cost-sharing design. These are expected observations, consistent with the intention of the plan design, yet still striking and informative in the context of rising public concern about underinsurance and medical debt among the insured.
Despite these COVID-19–related anomalies, our findings indicate that OOP spending rose for the majority of enrollees in our sample during the pre–COVID-19 era from 2012 to 2019, both in real dollars and as a share of total medical spending. OOP spending was also increasingly concentrated in the early months of the calendar year, with a growing gap in OOP spending between the first and fourth quarters.
These OOP spending trends affect both patients and health care providers. Nearly one-third of US workers with employer-sponsored coverage are enrolled in a high-deductible health plan, and adults with larger deductibles have reported higher rates of cost-related access problems.12,13 Some enrollees in high-deductible health plans may utilize a tax-advantaged health savings account (HSA) meant to encourage enrollees to be cost conscious while planning for care. Although we do not have information about HSAs in our data, previous research has found that enrollees with more wealth and a higher level of education are more likely to have an HSA and contribute more to these accounts than enrollees with less income and lower levels of education.14,15 Prior studies have also found that providers are less likely to collect the full patient obligation on larger bills,16 which indicates that the seasonal spikes in patient OOP obligations we observe may worsen providers’ collection rates.
The fact that high OOP spending obligations are often concentrated in a short time frame can pose additional financial difficulties for patients because only 37% of Americans could cover a $400 emergency expense with cash on hand.17,18 Considering the expense of high deductibles—the mean annual deductible was $1735 for workers with single coverage in an employer-sponsored plan in 2023—many patients are unable to fulfill their OOP obligations.3 Monthly or quarterly, rather than annual, caps on OOP spending have been proposed as a potential mechanism for addressing this consumption smoothing challenge.19 For example, a 2022 cross-sectional study of national commercial health insurance claims data suggested that a monthly OOP cap of $500 would affect 24.1% of the commercially insured.20 The authors estimate that such a cap would cut mean annual in-network spending almost in half but would result in a 5.6% increase to premiums.20 This trade-off highlights an important point: Reforms targeting OOP spending may help alleviate some financial pressures, but ultimately broader reforms that address the growing cost of health care are needed to improve affordability concerns writ large.
Limitations
Several limitations should be noted. First, these study findings may not be generalizable to commercial insurers beyond the analytic sample. In particular, the individual market was not represented in our sample. Additionally, our data use agreement restricts us from disaggregating enrollees by insurance carrier.
Second, our inclusion criteria requiring continuous coverage for a full calendar year excluded 31% of the initial sample of enrollees, representing 15% of unique claims and 17% of total medical spending. (Note that claims and spending are reported here as a percentage of annual claims and spending, but the excluded enrollees account for proportionally fewer months; that is, mean monthly spending within a given enrolled month is generally higher than mean monthly spending among full-year enrollees.) This differentially excluded people of different age groups such that individuals younger than 1 year, aged 25 to 34 years, and aged 55 to 64 years were disproportionately excluded from the analytic sample. We hypothesize that there is higher churning in these age groups due to dependents transitioning off parents’ coverage at aged 26 years, higher frequency of life events (eg, marriage) for those aged 25 to 34 years, and health shocks and retirement of primary enrollees aged 55 to 64 years. Additionally, newborns and their associated costs during that first year of life were excluded because they have less than a full calendar year of enrollment. The annual and quarterly spending trends reported in this study are not generalizable to individuals who enter a plan or drop a plan partway through the year.
Third, our study did not measure spending at the household level because our data lack identifiers to group family members enrolled in the same plan. Although it is possible there is some smoothing of OOP and total spending at the household level, nonetheless we believe the general patterns of our findings on spending trends are relevant regardless of whether subscribers are enrolled in individual or family coverage.
Fourth, our study did not evaluate spending on outpatient prescription drugs, which represents approximately one-fifth of total commercial spending overall.5 Our data did not include prescription drug claims for 47% of enrollees in our analytic sample, so we focused our primary analyses on medical spending. As a sensitivity analysis, we replicated our analysis using the subset of individuals with prescription drug coverage, including an analysis of their medical spending and their combined prescription and medical spending. Those analyses are shown in the eAppendix, and the findings are qualitatively similar.
Additionally, we did not observe whether individuals have access to flexible spending accounts or HSAs. Patients with these accounts to complement their high-deductible health plans may be less burdened by high OOP obligations than those without such accounts. We also did not directly observe the structure of cost sharing in plan design, such as OOP maximums and deductibles. Nonetheless, these findings provide important context for understanding household financial vulnerabilities and trends in medical collections practices and debt.
CONCLUSIONS
Health care spending is highly concentrated, and total spending growth among the highest spenders has driven overall average increases over the last decade. Insurance is working well to limit the financial burden of the highest spenders, whose portion paid OOP has been relatively flat despite their spending growth. However, subsidy increased across enrollees through cost-sharing design rather than further raising premiums. This is a trend to watch among rising public concerns about underinsurance, medical debt, and provider collections.
Author Affiliations: Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California (ELD, SG, SR, ET), Los Angeles, CA; Department of Pharmaceutical and Health Economics, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California (ET), Los Angeles, CA.
Source of Funding: Arnold Ventures.
Author Disclosures: Dr Duffy has provided expert testimony on matters in the hospital and health insurance sectors. Dr Trish has received grants from Arnold Ventures and The Commonwealth Fund, is a member of the editorial boards of The American Journal of Managed Care and Medical Care Research and Review, and has provided expert testimony on matters in the hospital, health insurance, health information technology, and life sciences sectors. The remaining authors report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.
Authorship Information: Concept and design (ELD, ET); acquisition of data (SG); analysis and interpretation of data (ELD, ET); drafting of the manuscript (ELD, SG, SR); critical revision of the manuscript for important intellectual content (SG, SR, ET); statistical analysis (ELD); obtaining funding (ET); administrative, technical, or logistic support (SR); and supervision (ET).
Address Correspondence to: Erin L. Duffy, PhD, MPH, Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California, 635 Downey Way, VPD 414F, Los Angeles, CA 90089-3333. Email: eld_805@usc.edu.
REFERENCES
1. Inflation, health costs, partisan cooperation among the nation’s top problems. Pew Research Center. June 21, 2023. Accessed September 1, 2023. https://www.pewresearch.org/politics/2023/06/21/inflation-health-costs-partisan-cooperation-among-the-nations-top-problems/
2. Murdock K, Kendall J, Kendall J. Medical debt hits the heart of the middle class. Third Way. August 21, 2023. Accessed September 1, 2023. https://www.thirdway.org/report/medical-debt-hits-the-heart-of-the-middle-class
3. Claxton G, Rae M, Winger A, Wager E. Employer Health Benefits 2023 Annual Survey. KFF; October 2023. Accessed December 15, 2023. https://files.kff.org/attachment/Employer-Health-Benefits-Survey-2023-Annual-Survey.pdf
4. Claxton G, Rae M, Damico A, Wager E, Young G, Whitmore H. Health benefits in 2022: premiums remain steady, many employers report limited provider networks for behavioral health. Health Aff (Millwood). 2022;41(11):1670-1680. doi:10.1377/hlthaff.2022.01139
5. 2020 Health Care Cost and Utilization Report. Health Care Cost Institute; May 2022. Accessed December 15, 2023. https://healthcostinstitute.org/images//pdfs/HCCI_2020_Health_Care_Cost_and_Utilization_Report.pdf
6. From Health Affairs: 2021 Costs For Employee-Sponsored Family Health Coverage. Health Affairs Forefront. November 10, 2021. Accessed December 15, 2023. https://www.healthaffairs.org/do/10.1377/forefront.20211109.950409
7. Hayes SL, Collins SR, Radley DC. How much U.S. households with employer insurance spend on premiums and out-of-pocket costs: a state-by-state look. The Commonwealth Fund. May 23, 2019. Accessed December 15, 2023. https://www.commonwealthfund.org/publications/issue-briefs/2019/may/how-much-us-households-employer-insurance-spend-premiums-out-of-pocket
8. Zhang X, Trish E, Sood N. Financial burden of healthcare utilization in consumer-directed health plans. Am J Manag Care. 2018;24(4):e115-e121.
9. Glied SA, Zhu B. Catastrophic out-of-pocket health care costs: a problem mainly for middle-income Americans with employer coverage. The Commonwealth Fund. April 17, 2020. Accessed December 15, 2023. https://bit.ly/3SOtZME
10. Holle M, Wolff T, Herant M. Trends in the concentration and distribution of health care expenditures in the US, 2001-2018. JAMA Netw Open. 2021;4(9):e2125179. doi:10.1001/jamanetworkopen.2021.25179
11. Parikh RB, Emanuel EJ, Zhao Y, et al. Spending patterns among commercially insured individuals during the COVID-19 pandemic. Am J Manag Care. 2023;29(10):517-521. doi:10.37765/ajmc.2023.89440
12. Doty MM, Ho A, Davis K. How High Is Too High? Implications of High-Deductible Health Plans. The Commonwealth Fund; April 1, 2005. Accessed December 15, 2023. https://bit.ly/3AlQWAy
13. Section 5: market shares of health plans. In: Employer Health Benefits 2021 Annual Survey. KFF; November 10, 2021:70-73. Accessed December 15, 2023. https://www.kff.org/report-section/ehbs-2021-section-5-market-shares-of-health-plans/
14. Glied SA, Remler DK, Springsteen M. Health savings accounts no longer promote consumer cost-consciousness. Health Aff (Millwood). 2022;41(6):814-820. doi:10.1377/hlthaff.2021.01954
15. Helmchen LA, Brown DW, Lurie IZ, Lo Sasso AT. Health savings accounts: growth concentrated among high-income households and large employers. Health Aff (Millwood). 2015;34(9):1594-1598. doi:10.1377/hlthaff.2015.0480
16. Chernew ME, Bush J. As patients take on more costs, will providers shoulder the burden? Health Affairs Forefront. May 4, 2017. Accessed December 15, 2023. https://www.healthaffairs.org/do/10.1377/forefront.20170504.059950
17. Economic Well-Being of U.S. Households in 2022. Board of Governors of the Federal Reserve System; May 2023. Accessed December 15, 2023. https://www.federalreserve.gov/publications/files/2022-report-economic-well-being-us-households-202305.pdf
18. Chen S, Shafer PR, Dusetzina SB, Horný M. Annual out-of-pocket spending clusters within short time intervals: implications for health care affordability. Health Aff (Millwood). 2021;40(2):274-280. doi:10.1377/hlthaff.2020.00714
19. Schafer PR, Horný M, Dusetzina SB. Rethinking annual deductibles: the case for monthly cost-sharing limits. Health Affairs Forefront. October 16, 2020. Accessed December 15, 2023. https://www.healthaffairs.org/do/10.1377/forefront.20201013.566424/full/
20. Shafer PR, Horný M, Dusetzina SB. Monthly cost-sharing limits and out-of-pocket costs for commercially insured patients in the US. JAMA Netw Open. 2022;5(9):e2233006. doi:10.1001/jamanetworkopen.2022.33006